Evidence for rCBV as an early response marker following bevacizumab treatment

Pope Whitney B.

首页> 外文期刊>Neuro-Oncology >Evidence for rCBV as an early response marker following bevacizumab treatment

【24h】

Evidence for rCBV as an early response marker following bevacizumab treatment

机译：贝伐单抗治疗后rCBV作为早期反应标志物的证据

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Neuro-Oncology》 |2015年第11期|1539-1540|共2页
作者
Pope Whitney B.;
展开▼
作者单位

Univ Calif Los Angeles, Los Angeles, CA 90095 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer [J] . Selcukbiricik F., Kanbay M., Solak Y., Clinical & translational oncology : . 2016,第11期

机译：血清尿酸是贝伐单抗治疗转移性结肠癌患者良好反应的替代指标
2. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment [J] . Boxerman Jerrold L., Schmainda Kathleen M., Zhang Zheng, Neuro-Oncology . 2015,第11期

机译：相对脑血容量的动态磁化率对比MRI测量继续显示出作为贝伐单抗治疗设置中的早期反应标志物的希望
3. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-beta, and/or bevacizumab for glioblastoma [J] . Ono Takahiro, Sasajima Toshio, Doi Yoshihiro, Nuclear Medicine and Biology . 2015,第7期

机译：氨基酸PET示踪剂是对胶质母细胞瘤单药或联合疗法（包括替莫唑胺，干扰素-β和/或贝伐单抗）的治疗反应的可靠标志物
4. Prediction of Glioblastoma Multiforme Response to Bevacizumab Treatment Using Diffusion and Perfusion Imaging [C] . Ehsan Abadi, Hamid Soltanian-Zadeh, Lisa Scarpace, Iranian Conference on Biomedical Engineering . 2015

机译：利用扩散和灌注成像预测胶质母细胞瘤对贝伐单抗治疗的响应
5. Lactate as a metabolic marker for LDH-A activity, metastatic capacity and treatment response in tumors. [D] . Rizwan, Asif. 2013

机译：乳酸作为LDH-A活性，转移能力和肿瘤治疗反应的代谢标志物。
6. Evidence for rCBV as an early response marker following bevacizumab treatment [O] . Whitney B. Pope 2015

机译：贝伐单抗治疗后rCBV作为早期反应标志物的证据
7. Detection of glioblastoma response to temozolomide combined with bevacizumab based on µMRI and µPET imaging reveals 18F-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy [O] . Aurélien Corroyer-Dulmont, Elodie A. Pérès, Edwige Petit, 2012

机译：基于μmRI和μpet成像的卵泡母细胞瘤与卵泡素相结合的胶质母细胞瘤响应显示18F -Fluoro-L-胸苷，作为治疗疗效的早期和稳健的预测标记

Evidence for rCBV as an early response marker following bevacizumab treatment

著录项

相似文献

相关主题

期刊订阅